Dr Noha Elkhider
About Dr Noha Elkhider
Dr. Noha Elkhider is a Senior Manager in Global Risk Management for Hematology at Bristol Myers Squibb in the United Kingdom, with extensive experience in drug safety and regulatory compliance.
Current Roles at Bristol Myers Squibb
Dr. Noha Elkhider is currently a Senior Manager in Global Risk Management (GRM) for Hematology at Bristol Myers Squibb, based in the United Kingdom. Additionally, she serves as a Drug Safety Senior Manager in London, England. Her responsibilities involve overseeing risk management and monitoring drug safety protocols to ensure compliance with regulatory guidelines and Good Pharmacovigilance Practices (GVP).
Previous Experience at Celgene
Dr. Elkhider worked at Celgene in various capacities from 2012 to 2021. She started as a Drug Safety Specialist, a role she held from 2012 to 2014. She then advanced to Associate Manager, Drug Safety from 2015 to 2018 and subsequently served as Drug Safety Manager from 2018 to 2021. During her tenure at Celgene, she was based in London, United Kingdom.
Educational Background
Dr. Elkhider holds a PhD in ATR-FTIR Spectroscopic Imaging of Pharmaceutical Formulations from Imperial College London, which she completed over six years from 2005 to 2011. She also achieved a Master's Degree in Pharmaceutical Analysis from Kingston University in 2002 and a Bachelor's Degree in Pharmaceutical Sciences from the same institution in 2000. Additionally, she completed her A-levels at West Thames College between 1994 and 1996, after attending Brentford School for Girls from 1992 to 1994.
Expertise in Pharmacovigilance
Dr. Elkhider has significant expertise in ensuring compliance with Good Pharmacovigilance Practices (GVP) and other regulatory requirements. She acts as a Subject Matter Expert for internal audits and Regulatory Authority inspections, and is responsible for documenting Corrective and Preventive Actions (CAPAs) and managing deviations related to Adverse Event (AE) processes. She also coordinates the flow of AE reports across regional and local drug safety offices and manages the Serious Adverse Event (SAE) reconciliation process using metrics-based process management.